Gilead forced to withdraw Truvada® patent application in Argentina
The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por: Julia Varela May 23, 2017 - In a resolution that means a step forward in safeguarding the right to health, Argentina’s patent office (the National Institute of Industrial Property - INPI) forced